- Aktivita fulvestrantu v expresi HER2 -- pokročilým karcinomem prsu2010 | 1. lékařská fakulta
- Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology2013 | 1. lékařská fakulta
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial2014 | 1. lékařská fakulta